Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2020, 29(4):205-212

Comment on the 2019 ESC/EASD Guidelines on diabetes, pre-diabetes and cardiovascular diseases

Fábryová Ľ1, 2, Martinka E3, Murín J4
1 MetabolKLINIK s.r.o, Ambulancia pre diabetológiu, poruchy látkovej premeny a výživy, MED PED centrum, Bratislava
2 Biomedicínske centrum Slovenskej Akadémie Vied, Bratislava
3 Národný endokrinologický a diabetologický ústav n. o., Ľubochňa
4 I. interná kliniky LFUK a UNB, Bratislava, Slovenská republika

Published: April 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fábryová Ľ, Martinka E, Murín J. Comment on the 2019 ESC/EASD Guidelines on diabetes, pre-diabetes and cardiovascular diseases. Cardiology Letters. 2020;29(4):205-212.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: Summary. Circulation. 2020;141:e139-e596. DOI: 10.1161/CIR.00000000000007
    2. Fábryová Ľ. Epidemiológia diabezity. In: Diabezita. Diabetes a obezita: nerozlučné dvojičky (Eds: Fábryová Ľ, Holéczy P.) Brno: Facta Medica; 2019:27-40. ISBN 978-80-88056-09-6.
    3. Národné centrum zdravotníckych informácií. Činnosť diabetologických ambulancií 2018. Bratislava, 2019. ZŠ-11/2019http:// www.nczi.sk
    4. Martinka E. Implementujeme aktuálne odporúčania ADA/EASD do liečby pacientov s diabetes mellitus 2. typu dostatočne? Forum Diab 2019;8:63-70.
    5. Cosentino F, Grant PJ, Aboyans V, et al. 2019 Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD. Eur Heart J 2020,2:255-323. https://doi.org/10.1093/eurheartj/ehz486 Go to original source...
    6. Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ2020;370:2297.doi: https://doi.org/10.1136/bmj.m2297 Go to original source...
    7. Huang Y, Liu L, Huang Ch, et al. Impacts of Pre-Diabetes or Prehypertension on Subsequent Occurrence of Cardiovascular and All-Cause Mortality among Population without Cardiovascular Diseases. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020;13:1743-1752. Go to original source...
    8. Ray KK, Colhoun HM, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:618-628. Go to original source...
    9. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2019.08.014> Go to original source...
    10. Goodarzi MO, Rotter JI. Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease. Circulation Research. 2020;126:1526-1548. DOI: 10.1161/ CIRCRESAHA.119.316065 Go to original source...
    11. Cao ZX, Zhang HW, Jin JL, et al. The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes. Cardiovasc Diabetol 2020;19:104. https://doi.org/10.1186/s12933-020-01076-7 Go to original source...
    12. Chait A, Ginsberg HN, Vaisar T, et al. Remnants of the TriglycerideRich Lipoproteins, Diabetes and Cardiovascular Disease. Diabetes 2020;69:508-516.https://doi.org/10.2337/dbi19-0007 Go to original source...
    13. Sandesara PB, Virani SS, Fazio S, et al. The forgotten lipids: trigly­ cerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev 2019;40:537-557. Go to original source...
    14. Bhatt DL, Steg PG, Mille M, et al. REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11-22. Go to original source...
    15. Marston NA, Giugliano RP, KyungAh I, et al. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019;140:1308-1317. DOI: 10.1161/CIRCULATIONAHA.119.041998 Go to original source...
    16. PradhanAD, Paynter NP, Everett BM, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018;206:80-93. Go to original source...
    17. Buse JB, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care Publish Ahead of Print, published online December 19, 2019 https://doi.org/10.2337/dci19-0066 Go to original source...
    18. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020 Jan;43(Supplement 1):S98-S110. https://doi.org/10.2337/dc20-S009 Go to original source...
    19. Gerstein HC, et al. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-130. Go to original source...
    20. Husain M, et al. PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381:841-851. Go to original source...
    21. Patorno E, Pawar A, Franklin JM, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the empagliflozin comparative effectiveness and safety (EMPRISE) Study. Circulation. 2019;139:2822-2830. <https://doi.org/10.1161/CIRCULATIONAHA.118.039177 Go to original source...
    22. Fábryová Ľ. Rizikové faktory aterosklerózy v populácii novodiagnostikovaných diabetikov 2. typu. Dizertačná práca. Bratislava: Lekárska Fakulta Univerzity Komenského; 2008:108.
    23. Ryde´n L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035-3087. Go to original source...
    24. Gomes CP, Schroen B, Kuster GM, et al. Regulatory RNAs in Heart Failure. Circulation. 2020;141:313-328. DOI: 10.1161/ CIRCULATIONAHA.119.042474 Go to original source...
    25. Linssen P, Veugen M, Henry R, et al. Associations of (pre)diabetes with right ventricular and atrial structure and function: the Maastricht Study. Cardiovasc Diabetol 2020;19:88. https://doi.org/10.1186/s12933-020-01055-y Go to original source...

    Return to the content